Paper28845751
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Ridker PM and 28 others. N Engl J Med, 2017. Cited by 7,792 papers, by iCite.
Cite this record
ConductScience Library. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. Papers, record 28845751. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28845751
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Inflammatory Agents | Major topic |
| Antibodies, Monoclonal | Major topic |
| Atherosclerosis | Major topic |
| Interleukin-1beta | Major topic |
| Myocardial Infarction | Major topic |
| Aged | |
| Antibodies, Monoclonal, Humanized | |
| C-Reactive Protein | |
| Cardiovascular Diseases | |
| Dose-Response Relationship, Drug | |
| Double-Blind Method | |
| Female | |
| Humans | |
| Incidence | |
| Infections | |
| Lipids | |
| Male | |
| Middle Aged | |
| Neutropenia | |
| Secondary Prevention | |
| Stroke |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| K23 NS073806 | NINDS NIH HHS | United States | K23NS073806 | PubMed and NIH |
Source NIH RePORTER
Trials12
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT01327846 | Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT03869268 | The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin | Background | ClinicalTrials.gov | |
| NCT04148833 | Treatment of Patients With Atherosclerotic Disease With Paclitaxel-associated to LDL Like Nanoparticles | Background | ClinicalTrials.gov | |
| NCT04616872 | Treatment of Patients With Atherosclerotic Disease With Methotrexate-associated to LDL Like Nanoparticles | Background | ClinicalTrials.gov | |
| NCT04735874 | Vascular Health and Risk Factors in Children With Down Syndrome | Background | ClinicalTrials.gov | |
| NCT04990791 | WILL lOWer Dose Aspirin be Better With Rivaroxaban in Patients With Chronic Coronary Syndromes? | Background | ClinicalTrials.gov | |
| NCT05131750 | RIR and the Impact on Clinical Outcomes in Patients Undergoing PCI | Results | ClinicalTrials.gov | |
| NCT05908513 | NAC Treatment and Outcomes in Patients With Advanced Atherosclerosis and DM | Background | ClinicalTrials.gov | |
| NCT05956145 | Effect of Low Dose of Colchicine on Platelet Reactivity | Background | ClinicalTrials.gov | |
| NCT06216847 | Clinical Outcomes of Patients With Coronary Artery Disease | Background | ClinicalTrials.gov | |
| NCT07129850 | Bempedoic Acid in PPCI Impact on Clinical Outcome and Inflammatory Markers | Results | ClinicalTrials.gov | |
| NCT07331103 | RESOLving INflammation Through Diet for Health (RESOLVIN) | Background | ClinicalTrials.gov |
Comments and corrections13
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 28844177 | Targeting Inflammation in Coronary Artery Disease. | https://conductscience.org/library/papers/28844177 | PubMed |
| Comment in | 28905870 | Inflammation: Targeting inflammatory pathways to treat atherosclerosis and cancer. | https://conductscience.org/library/papers/28905870 | PubMed |
| Comment in | 29056511 | CANTOS Ushers in a New Calculus of Inflammasome Targeting for Vascular Protection-and Maybe More. | https://conductscience.org/library/papers/29056511 | PubMed |
| Comment in | 29074528 | CANTOS Trial Validates the Inflammatory Pathogenesis of Atherosclerosis: Setting the Stage for a New Chapter in Therapeutic Targeting. | https://conductscience.org/library/papers/29074528 | PubMed |
| Comment in | 29312693 | The Canakinumab Antiinflammatory Thrombosis Outcome Study trial-the starting gun has fired. | https://conductscience.org/library/papers/29312693 | PubMed |
| Comment in | 29322754 | Canakinumab for Atherosclerotic Disease. | https://conductscience.org/library/papers/29322754 | PubMed |
| Comment in | 29322755 | Canakinumab for Atherosclerotic Disease. | https://conductscience.org/library/papers/29322755 | PubMed |
| Comment in | 29322756 | Canakinumab for Atherosclerotic Disease. | https://conductscience.org/library/papers/29322756 | PubMed |
| Comment in | 29322757 | Canakinumab for Atherosclerotic Disease. | https://conductscience.org/library/papers/29322757 | PubMed |
| Comment in | 29322758 | Canakinumab for Atherosclerotic Disease. | https://conductscience.org/library/papers/29322758 | PubMed |
| Comment in | 29367331 | Effect size in CANTOS trial. | https://conductscience.org/library/papers/29367331 | PubMed |
| Comment in | 29600023 | The quest for immunotherapy in atherosclerosis: CANTOS study, interleukin-1β and vascular inflammation. | https://conductscience.org/library/papers/29600023 | PubMed |
| Comment in | 29607136 | Anti-inflammatory therapy with canakinumab for atherosclerotic disease: lessons from the CANTOS trial. | https://conductscience.org/library/papers/29607136 | PubMed |
Cited by5,182
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7,792 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42985198 | Biomarkers for the diagnosis and management of cardiovascular-kidney-metabolic syndrome: recent advances and prospects for clinical application. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/42985198 | PubMed |
| 42985003 | A whole-blood transcriptomic analysis of shared molecular mechanisms between subclinical atherosclerosis and hypothyroidism in women. | Front Bioinform | 2026 | https://conductscience.org/library/papers/42985003 | PubMed |
| 42983562 | Chlamydia pneumoniae orchestrates a multi-stage signaling network in atherosclerosis: from endothelial dysfunction to plaque vulnerability. | Cell Commun Signal | 2026 | https://conductscience.org/library/papers/42983562 | PubMed |
| 42979406 | Dendritic cells in atherosclerosis: integrating ontogeny, functional states, spatial organization, and therapeutic implications. | Front Immunol | 2026 | https://conductscience.org/library/papers/42979406 | PubMed |
| 42979111 | Five Trials, Five Different Questions: Design Heterogeneity Among Lipoprotein(a)-Lowering Cardiovascular Outcomes Trials After Lp(a)HORIZON. | Cureus | 2026 | https://conductscience.org/library/papers/42979111 | PubMed |
| 42979076 | NLRP3 signalling in NSCLC: distinguishing expression, inflammasome activation and context-dependent function. | Front Immunol | 2026 | https://conductscience.org/library/papers/42979076 | PubMed |
| 42978947 | Dressler syndrome and post-cardiac injury syndrome: an autoinflammatory framework for reappraising a seventy-year-old diagnosis: a state-of-the-art review. | Front Immunol | 2026 | https://conductscience.org/library/papers/42978947 | PubMed |
| 42977812 | Hematopoietic loss of KDM6A impairs cardiac recovery in heart failure via epigenetic reprogramming of myeloid cells. | Nat Cardiovasc Res | 2026 | https://conductscience.org/library/papers/42977812 | PubMed |
| 42974282 | Understanding and translating evolutionary adaptations in animals exposed to contaminated diets to guide strategies against human foodborne disease: a prioritisation framework. | Front Immunol | 2026 | https://conductscience.org/library/papers/42974282 | PubMed |
| 42974193 | Extracellular ATP Signaling as a Proposed Mechanistic Link to Cellular Senescence in Cardiovascular Diseases. | J Inflamm Res | 2026 | https://conductscience.org/library/papers/42974193 | PubMed |
| 42974013 | Strategies to reduce microvascular obstruction and infarct size in patients with ST-elevation myocardial infarction. | Front Cardiovasc Med | 2026 | https://conductscience.org/library/papers/42974013 | PubMed |
| 42973842 | Immune-driven remodeling in calcific aortic valve disease: mechanisms and immunotherapeutic opportunities. | Front Immunol | 2026 | https://conductscience.org/library/papers/42973842 | PubMed |
| 42973829 | Cross-cohort blood transcriptome analysis identifies an eight-gene diagnostic index and inflammatory programs in acute myocardial infarction. | Front Cardiovasc Med | 2026 | https://conductscience.org/library/papers/42973829 | PubMed |
| 42973467 | Association between the perivascular fat attenuation index and CCTA-defined anatomically significant left anterior descending coronary artery stenosis: relationship with serum inflammatory biomarkers. | Front Cardiovasc Med | 2026 | https://conductscience.org/library/papers/42973467 | PubMed |
| 42972542 | Pregnancy loss and prevalent cardiometabolic multimorbidity: a two-stage individual participant data analysis of CHARLS, ELSA, and HRS. | BMC Womens Health | 2026 | https://conductscience.org/library/papers/42972542 | PubMed |
| 42965583 | Cellular senescence in calcific aortic valve disease: are we ready for senolytic therapy? | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42965583 | PubMed |
| 42963430 | Cholesterol binding stabilizes the activated state of THIK-1 and promotes atherosclerosis. | EMBO Rep | 2026 | https://conductscience.org/library/papers/42963430 | PubMed |
| 42961237 | Beyond LDL-Cholesterol: Can the Neutrophil-to-HDL-Cholesterol Ratio Capture Residual Inflammatory Risk? | Arq Bras Cardiol | 2026 | https://conductscience.org/library/papers/42961237 | PubMed |
| 42959490 | Cardiovascular Risk of Conventional Synthetic, Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Common Rheumatic Diseases: A Narrative Review of Current Evidence. | Ther Clin Risk Manag | 2026 | https://conductscience.org/library/papers/42959490 | PubMed |
| 42959445 | Atherosclerosis: From Pathogenesis to Therapeutic Interventions. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42959445 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CRP | 1401 | PubTator's text mining | https://conductscience.org/library/genes/1401 | NCBI Gene |
| IL1B | 3553 | PubTator's text mining | https://conductscience.org/library/genes/3553 | NCBI Gene |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| CANAKINUMAB | CHEMBL1201834 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL1201834 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- References
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28845751
GET https://conductscience.org/api/papers/v1/28845751/authors?page=2